导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.05% | 4326/4773 |
| 近一周 | -4.29% | 5075/5465 |
| 近一月 | -6.05% | 4018/5421 |
| 近一季 | -3.20% | 1574/5231 |
| 近半年 | -22.89% | 4572/4920 |
| 近一年 | -23.62% | 4047/4394 |
| 近两年 | 41.48% | 1837/2954 |
| 近三年 | 9.12% | 1783/2253 |
| 成立以来 | 45.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.66% 2410/4961 |
-16.79% 4742/5312 |
- - |
- - |
| 2025 | 29.51% 1393/4813 |
5.94% 705/3635 |
5.41% 593/4076 |
23.25% 1559/4524 |
-5.91% 3642/4813 |
| 2024 | 8.04% 1596/3463 |
2.19% 808/2808 |
-17.02% 2744/3014 |
21.70% 553/3129 |
4.70% 677/3463 |
| 2023 | 21.36% 16/2656 |
40.53% 24/2280 |
6.02% 50/2385 |
-13.41% 2152/2515 |
-5.93% 1564/2655 |
| 2022 | -28.75% 1578/2207 |
-21.64% 1644/1919 |
-3.30% 1810/2016 |
-17.29% 1578/2113 |
13.68% 96/2208 |
| 2021 | 6.54% 512/1822 |
-6.83% 1040/1255 |
4.33% 898/1330 |
-11.38% 1266/1466 |
23.68% 10/1822 |
| 2020 | - - |
- - |
- - |
3.52% 979/1164 |
-8.15% 1159/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证传媒ETF VS. 长安沪深300非周期A(740101) |